Food for Thought - Dream or Reality ?7 Dec 2024 09:55
Interesting opinions & summary by Don Von Posen posted on X.
1/ Tiziana Life Sciences Update Hypothesis
With the recent expansion of Tiziana's Phase 2 trial for Foralumab to major US
institutions like Yale & Johns Hopkins, let’s dive into what this means and why
silence from the company might actually be a good thing.
2/ The Context:
Foralumab, Tiziana's lead asset, targets non-active secondary progressive
multiple sclerosis (SPMS)—a massive unmet need. Trial expansion follows
promising results from the first 10 patients. But why expand now, and why
the radio silence?
3/ Hypothesis: Big Pharma's Influence?
Expansion to top-tier sites like Yale may not just be for better data. Could
it be feedback from Big Pharma? These companies might be advising Tiziana
to generate broader data before committing to a deal.
4/ A Strategic Move?
With SPMS lacking FDA-approved treatments, Foralumab has first-in-class
potential. Expanding trials while generating robust data shows confidence
in results—and signals a possible deal in the works.
5/ Financial Moves Align with Strategy:
Recent $5M fundraise is small, more of a bridge than a long-term runway.
This suggests Tiziana may already anticipate significant external funding
via partnerships or licensing.
6/ Why the Silence?
Silence ≠ inactivity. Non-disclosure agreements (NDAs) during negotiations
could limit what Tiziana can share publicly. Big Pharma typically demands
thorough due diligence before signing deals.
7/ Why is This Exciting?
Foralumab's intranasal delivery method offers unique benefits in
neurodegenerative diseases like SPMS, Alzheimer's, and Parkinson's.
Recent Ozempic combo results only increase Foralumab’s value.
8/ TL;DR: The Big Picture:
Tiziana seems to be playing a long game—expanding trials strategically,
raising just enough funds, and working towarda potential Big Pharma deal.
Silence could mean something BIG is coming
11/ ALS Grant Adds Momentum:
Tiziana received a grant to explore Foralumab’s use in ALS, expanding its
pipeline & boosting its appeal to partners. Another step toward unlocking
its full commercial potential! .
12/ Ozempic Synergy:
Foralumab + Ozempic (semaglutide) showed anti-inflammatory & liver
health benefits in obesity models. Could Novo Nordisk or a GLP-1 player step
in for a deal ?.
13/ What’s Next?
With SPMS trial expansion, ALS grant, Ozempic synergy, & a strategic fundraising,
Tiziana is positioning itself for major moves. IMO, the silence speaks volumes
Big Pharma could be circling. Not advice, just my view! Let’s see what happens.
Sign In
Follow the stocks
